Palvella Therapeutics (PI6) Price & Analysis

0 Followers

PI6 Stock Chart & Stats

€126.00

€2.00(1.63%)

At close: Jul 24 4:00 PM EDT

€126.00

€2.00(1.63%)

Day’s Range― - ―

52-Week Range€60.00 - €137.00

Previous CloseN/A

Volume0.00

Average Volume (3M)12.00

Market Cap

€1.61B

Enterprise Value€1.97B

Total Cash (Recent Filing)€250.58M

Total Debt (Recent Filing)€535.00K

Price to Earnings (P/E)―

Beta0.54

Next Earnings

Nov 17, 2026

EPS Estimate

-1.6

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.83

Shares Outstanding14,408,407

10 Day Avg. Volume0

30 Day Avg. Volume12

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)42.09

Price to Sales (P/S)0.00

P/FCF Ratio-47.10

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€206.93

Price Target Upside64.23% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)-5.87

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Phase III Clinical EfficacyThe successful Phase III results provide substantial clinical validation for QTORIN rapamycin in a serious rare disease. A high response rate across multiple endpoints can support regulatory review, physician adoption and a stronger commercial foundation if the product is approved.

Advanced Regulatory ProgressRolling review and an initial NDA module submission show that the lead program has moved beyond development into an active regulatory process. This shortens the path to a potential 2027 launch and gives the company a defined near-term value-creation milestone.

Strong Balance Sheet And Financing SupportThe sizeable cash position and recent financing provide resources to complete regulatory work and build launch capabilities without the immediate pressure of minimal liquidity. Very low debt further reduces financial risk while Palvella advances its lead program toward commercialization.

Bears Say

No Current Commercial Revenue And Large LossesPalvella has not yet established recurring product sales, so its financial performance remains dependent on research progress rather than commercial execution. Persistent large losses reduce near-term earnings visibility and leave future value highly dependent on successful approval and launch.

Persistent Cash Burn And External Financing DependenceNegative operating and free cash flow means the business is not self-funding and continues to consume capital while advancing its pipeline. Even with substantial cash on hand, prolonged development and launch spending may require additional financing if commercialization is delayed.

Regulatory And Commercialization Execution Remains UnfinishedThe lead product still must complete the NDA and pass regulatory review before revenue can begin, while broader indication expansion depends on lengthy additional trials. This creates execution and timing risk around launch readiness, approvals and the pace of market expansion.

Palvella Therapeutics News

Clear Street sees positive read for Palvella from FDA rare disease framework

Noting that the FDA launched its Rare Disease Framework Initiative on October 14, Clear Street sees “meaningful positive...

4d ago

PVLA

Raymond James says new data supportive of broad label for Qtorin

Raymond James analyst Ryan Deschner keeps a Strong Buy rating on Palvella Therapeutics (PVLA) announced yesterday morning the...

8d ago

PVLA

Palvella Therapeutics initiated with an Outperform at William Blair

William Blair initiated coverage of Palvella Therapeutics (PVLA) with an Outperform rating. Palvella is a rare disease company...

9d ago

PVLA

Palvella Therapeutics price target lowered to $246 from $270 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Palvella Therapeutics (PVLA) to $246 from $270 and keeps a...

12d ago

PVLA

Palvella Therapeutics management to meet with Truist

Meeting to be held in Boston on October 6 hosted by Truist. Published first on TheFly – the...

18d ago

PVLA

Palvella receives third year of grant funding from FDA for QTORIN

Palvella Therapeutics (PVLA) announced that the Company has received a third year of grant funding from the FDA...

26d ago

PVLA

Palvella Therapeutics transferred with Buy rating at Chardan

Chardan kept a Buy rating on Palvella Therapeutics (PVLA) with a $240 price target following a transfer of...

1M ago

PVLA

Palvella Therapeutics completes rolling submission of Qtorin NDA to FDA

Palvella Therapeutics (PVLA) announced that the company has completed the rolling submission of its new drug application, or...

2M ago

PVLA

Palvella Therapeutics price target lowered to $207 from $210 at Truist

Truist lowered the firm’s price target on Palvella Therapeutics (PVLA) to $207 from $210 and keeps a Buy...

3M ago

PVLA

Palvella Therapeutics price target raised to $232 from $227 at Canaccord

Canaccord raised the firm’s price target on Palvella Therapeutics (PVLA) to $232 from $227 and keeps a Buy...

3M ago

PVLA

Palvella Therapeutics: Strong Cash Runway and High-Confidence QTORIN Rapamycin Outlook Underpin New Buy Rating

In a report released yesterday, Ritu Baral from TD Cowen maintained a Buy rating on Palvella Therapeutics, with...

3M ago

PVLA

High-Risk Warning for Investors in Palvella Therapeutics Securities

Palvella Therapeutics, Inc. (PVLA) has disclosed a new risk, in the Regulation category. An external review indicates that...

3M ago

PVLA

Palvella Therapeutics Charts Clear Path From Data To Launch

Palvella Therapeutics, Inc. (($PVLA)) has held its Q2 earnings call. Read on for the main highlights of the...

3M ago

PVLA

Palvella details QTORIN progress and Nasdaq uplisting milestones

An announcement from Palvella Therapeutics ( ($PVLA) ) is now available. On August 4, 2026, Palvella Therapeutics reported...

3M ago

PVLA

PI6 FAQ

What was Palvella Therapeutics’s price range in the past 12 months?

Palvella Therapeutics lowest stock price was €60.00 and its highest was €137.00 in the past 12 months.

What is Palvella Therapeutics’s market cap?

Palvella Therapeutics’s market cap is €1.61B.

When is Palvella Therapeutics’s upcoming earnings report date?

Palvella Therapeutics’s upcoming earnings report date is Nov 17, 2026 which is in 24 days.

How were Palvella Therapeutics’s earnings last quarter?

Palvella Therapeutics released its earnings results on Aug 04, 2026. The company reported -€1.357 earnings per share for the quarter, missing the consensus estimate of -€1.047 by -€0.31.

Is Palvella Therapeutics overvalued?

According to Wall Street analysts Palvella Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Palvella Therapeutics pay dividends?

Palvella Therapeutics does not currently pay dividends.

What is Palvella Therapeutics’s EPS estimate?

Palvella Therapeutics’s EPS estimate is -1.6.

How many shares outstanding does Palvella Therapeutics have?

Palvella Therapeutics has 14,408,407 shares outstanding.

What happened to Palvella Therapeutics’s price movement after its last earnings report?

Palvella Therapeutics reported an EPS of -€1.357 in its last earnings report, missing expectations of -€1.047. Following the earnings report the stock price went up 1.681%.

Which hedge fund is a major shareholder of Palvella Therapeutics?

Currently, no hedge funds are holding shares in DE:PI6

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Palvella Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-47.84%

Trailing 12-Months

Asset Growth

243.76%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Palvella Therapeutics

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.

Palvella Therapeutics (PI6) Earnings & Revenues

Historic Earnings Reports

PI6 Company Deck

PI6 Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call highlights substantial clinical and regulatory progress—compelling Phase III SELVA results (95% improvement on primary endpoint), rolling review and first NDA module submission—supported by strong financial resources (~$251M cash) and accelerated commercial hiring (≈40 reps). Near-term risks include the need to complete the NDA, initial lack of Breakthrough for cVM (to be addressed with additional 24‑week data and qualitative evidence), increased 2026 cash spend to accelerate launch readiness, and multi-year timelines to expand indications beyond microcystic LMs. Overall, the positive clinical data, regulatory momentum, funding and clear commercial plan meaningfully outweigh the challenges and remaining execution risks.View all DE:PI6 earnings summaries

PI6 Stock 12 Month Forecast

Average Price Target

€206.93

▲(64.23% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"52":"€52","145":"€145","238":"€238","98.5":"€98.5","191.5":"€191.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":237.72340995,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€237.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":206.9321443041667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€206.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":184.30241895,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€184.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[52,98.5,145,191.5,238],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,121,129.9787238423077,138.95744768461537,147.93617152692306,156.91489536923075,165.89361921153846,174.87234305384615,183.85106689615384,192.82979073846153,201.8085145807692,210.7872384230769,219.7659622653846,228.7446861076923,{"y":237.72340995,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,121,127.61016494647436,134.2203298929487,140.8304948394231,147.44065978589745,154.0508247323718,160.66098967884616,167.27115462532055,173.8813195717949,180.49148451826926,187.10164946474362,193.71181441121797,200.32197935769233,{"y":206.9321443041667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,121,125.86941684230769,130.73883368461537,135.6082505269231,140.47766736923077,145.34708421153846,150.21650105384614,155.08591789615383,159.95533473846154,164.82475158076923,169.69416842307692,174.56358526538463,179.4330021076923,{"y":184.30241895,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >